Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

It’s natural to view the rise of GLP-1 weight-loss medications as yet another trend in the health and medical space. But given the prevalence of obesity in the United States—and the significant ...

Baker Mayfield has spent his NFL career defying expectations, critics, and roster uncertainties. Yet Sunday’s 23–20 defeat to the Carolina Panthers felt different — less like a temporary setback and ...

WASHINGTON — New analysis suggests that problems with NASA’s MAVEN Mars orbiter may be more serious than a simple communications glitch. NASA said Dec. 9 that it lost contact with the spacecraft three ...

NASA has lost contact with its MAVEN spacecraft, which has been orbiting Mars for over a decade. The loss of signal occurred on Dec. 6 as the orbiter passed behind Mars from Earth's perspective. MAVEN ...

Rivian impressed Wall Street analysts on Thursday with its plans for AI and automation, but significant challenges involving demand and capital remain for the electric vehicle maker. That's according ...

One of NASA’s workhorse spacecraft in orbit around Mars has fallen silent, leaving agency personnel scrambling to troubleshoot the issue. The Mars Atmosphere and Volatile Evolution (MAVEN) mission ...

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

Archetype AI Inc., a startup that provides artificial intelligence agents optimized to process sensor data, has raised $35 million in early-stage funding. IAG Capital Partners and Hitachi Ventures led ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...